Please login to the form below

Not currently logged in
Email:
Password:

Cushing's disease

This page shows the latest Cushing's disease news and features for those working in and with pharma, biotech and healthcare.

Novartis' acromegaly therapy cleared by FDA

Novartis' acromegaly therapy cleared by FDA

It leads to an increase in bone size, particularly those in the hands, feet and face, alongside other complications such as diabetes, arthritis, kidney disease and cancer. ... A short-acting formulation of Signifor that requires twice-daily dosing is

Latest news

  • Novartis gets EU nod for rare disease drug Signifor Novartis gets EU nod for rare disease drug Signifor

    Signifor (pasireotide) was first approved in Europe in 2012 as a twice-daily subcutaneous injection for Cushing's disease, but the new depot formulation - called Signifor LAR - requires just one intramuscular ... It is also testing the new formulation

  • Novartis plans filings for acromegaly candidate Novartis plans filings for acromegaly candidate

    A twice-daily formulation of Signifor (pasireotide) is already on the market for the treatment of Cushing's disease, but the latest study assessed a once-monthly intramuscular formulation - called Signifor ... The company has already filed for approval

  • Novartis cancer chief Hoppenot leaves for top job at Incyte Novartis cancer chief Hoppenot leaves for top job at Incyte

    During his time at the helm of Novartis' cancer division Hoppenot presided over the launch of two new cancer therapies, Jakavi for myelofibrosis in 2011 and Signifor (pasireotide) for Cushing's ... disease in 2012, while rolling out new indications for

  • Novartis provides multimedia support to Rare Diseases Day Novartis provides multimedia support to Rare Diseases Day

    The initiative includes fact sheets, infographics and advice on diseases such as  Cushing's disease, gastrointestinal stromal tumor (GIST), chronic myeloid leukemia etc. ... In addition, a 'Rare Diseases Hour' has been incorporated into Novartis'

  • Fast flourish

    drug compound, AF267B, is safe to use on patients suffering from Alzheimer's disease. ... treats Cushing's disease in dogs.

More from news
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    GSK's current and future oncology R&D pipeline becoming its preferred commercialisation partner. ... Jakavi (rare bone marrow disorder); Signifor (Cushing's disease) plus 16 products in 24 pivotal trials. .

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics